Skip to main content
. Author manuscript; available in PMC: 2012 Aug 15.
Published in final edited form as: Cancer Res. 2011 Jul 5;71(16):5467–5476. doi: 10.1158/0008-5472.CAN-10-3988

Figure 3. Kinetics of IL-10 secretion explains inflammatory capacity of TLR agonists.

Figure 3

MoDCs were monitored for the secretion of IL-12p70 and IL-10 when either untreated or stimulated with LPS, PolyI:C, LPS/PolyI:C, R848, R848/LPS, R848/PolyI:C and Mimic. IL-12p70 and IL-10 was also monitored using the same conditions with or without blocking IL-10 and IL-10R, and with or without pretreatment with recombinant IL-10 (A, B respectively). The same experiment was repeated by monitoring IL-12p70 and IL-10 in supernatants collected over time (C, D respectively). Each experiment was performed in triplicates and repeated at least with 3 different donors.